# Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1060469 in Healthy Asian Male Volunteers

> **NCT02183545** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 80 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 1060469
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02183545
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2014-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02183545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02183545, "Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1060469 in Healthy Asian Male Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02183545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*